NCT06764875 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT06764875
Title	A Phase III Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	AstraZeneca
Indications	stomach cancer gastroesophageal junction adenocarcinoma
Therapies	Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab Cisplatin + Fluorouracil + Pembrolizumab + Trastuzumab AZD2936 + Capecitabine + Oxaliplatin + Trastuzumab AZD2936 + Cisplatin + Fluorouracil + Trastuzumab AZD2936 + Fluorouracil + Trastuzumab deruxtecan AZD2936 + Capecitabine + Trastuzumab deruxtecan
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| POL \| NLD \| ITA \| HUN \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG

No variant requirements are available.